Baseline characteristics
| . | Prior therapy . | All . | P . | |
|---|---|---|---|---|
| Targeted . | CIT . | |||
| Total, N | 30 | 78 | 108 | |
| Age, median (range), y | 60 (30-71) | 59 (26-73) | 59 (26-73) | .36 |
| Sex, n (%) | .22 | |||
| Male | 25 (83.3) | 55 (70.5) | 80 (74.1) | |
| Female | 5 (16.7) | 23 (29.5) | 28 (25.9) | |
| Patient-donor sex match, n (%) | .13 | |||
| Male ← Female | 10 (33.3) | 15 (19.2) | 25 (23.1) | |
| Disease status at HCT, n (%) | .47 | |||
| CR | 6 (20) | 21 (26.9) | 27 (25) | |
| PR | 22 (73.3) | 56 (71.8) | 78 (72.2) | |
| Relapse | 1 (3.3) | 1 (1.3) | 2 (1.9) | |
| Induction failure | 1 (3.3) | 1 (0.9) | ||
| ECOG PS, n (%) | .16 | |||
| 0 | 5 (16.7) | 18 (23.1) | 23 (21.3) | |
| 1 | 18 (60) | 51 (65.4) | 69 (63.9) | |
| 2 | 7 (23.3) | 9 (11.5) | 16 (14.8) | |
| Patient and donor CMV serostatus, n (%) | .34 | |||
| R−/D− | 6 (20) | 26 (33.3) | 32 (29.6) | |
| R−/D+ | 8 (26.7) | 12 (15.4) | 20 (18.5) | |
| R+/D− | 11 (36.7) | 23 (29.5) | 34 (31.5) | |
| R+/D+ | 5 (16.7) | 17 (21.8) | 22 (20.4) | |
| HCT-comorbidity score, n (%) | .56 | |||
| 0 | 13 (43.3) | 39 (50) | 52 (48.1) | |
| 1 | 3 (10) | 13 (16.7) | 16 (14.8) | |
| 2 | 4 (13.3) | 9 (11.5) | 13 (12) | |
| ≥3 | 10 (33.3) | 17 (21.8) | 23 (25) | |
| No. of prior therapies | .41 | |||
| 1, n (%) | 2 (6.7) | 9 (11.5) | 11 (10.2) | |
| 2-3, n (%) | 12 (40) | 38 (48.7) | 50 (46.3) | |
| ≥4, n (%) | 16 (53.3) | 31 (39.7) | 47 (43.5) | |
| Median (range) | 4 (1-9) | 3 (1-10) | 3 (1-10) | .1 |
| Time from first CLL tx to alloHCT, mo* | .35 | |||
| Median (range) | 39.5 (6.7-173.3) | 39.1 (4.2-151.6) | 39.1 (4.2-151.6) | |
| Targeted therapy prior to HCT, n (%) | NA | |||
| Ibrutinib | 19 (63.3) | 20 (18.5) | ||
| Ibrutinib/idelalisib | 1 (3.3) | 2 (1.9) | ||
| Ibrutinib/venetoclax | 5 (16.7) | 4 (3.7) | ||
| Ibrutinib/CART19/ibrutinib2/venetoclax | 1 (3.3) | 1 (0.9) | ||
| Ibrutinib/idelalisib/ibrutinib2/venetoclax | 1 (3.3) | |||
| Venetoclax | 3 (10) | 3 (2.8) | ||
| HLA type (at A, B, C, DRB1), n (%) | .1 | |||
| 8/8 MRD | 10 (33.3) | 19 (24.4) | 29 (26.9) | |
| 8/8 MUD | 13 (43.3) | 50 (64.1) | 63 (58.3) | |
| 7/8 MUD | 7 (23.3) | 6 (7.7) | 13 (12) | |
| 5/8 MRD | 1 (1.3) | 1 (0.9) | ||
| 5/8 MUD | 2 (2.6) | 2 (1.9) | ||
| Cell source, n (%) | .7 | |||
| BM | 2 (2.6) | 2 (1.9) | ||
| PBSC | 30 (100) | 74 (94.9) | 104 (96.3) | |
| Double cord | 2 (2.6) | 2 (1.9) | ||
| GVHD prophylaxis, n (%) | .14 | |||
| Calcineurin inhibitor/Sir/MTX | 22 (73.3) | 43 (55.1) | 65 (60.2) | |
| Calcineurin inhibitor/MTX | 3 (10) | 21 (26.9) | 24 (22.2) | |
| Other | 5 (16.7) | 14 (18.0) | 19 (17.6) | |
| RIC regimen, n (%) | .009 | |||
| Flu/Bu1 | 7 (23.3) | 48 (61.5) | 55 (50.9) | |
| Flu/Bu2 | 21 (70) | 27 (34.6) | 48 (44.4) | |
| Other | 2 (6.7) | 3 (3.8) | 5 (4.6) | |
| WBC count, ×109/L | .001 | |||
| <2, n (%) | 2 (6.7) | 18 (23.1) | 20 (18.5) | |
| 2-10, n (%) | 21 (70) | 57 (73.1) | 78 (72.2) | |
| >10, n (%) | 7 (23.3) | 3 (3.8) | 10 (9.3) | |
| Median (IQR) | 4.6 (3.3-8.8) | 3.3 (2.1-4.7) | 3.7 (2.2-5.5) | .002 |
| % BM involvement | .22 | |||
| Median (IQR) | 5 (5-15) | 5 (5-10) | 5 (5-14) | |
| UNK, n | 1 | 9 | 10 | |
| LDH | ||||
| Median (IQR) | 164 (150-209) | 196 (155-230) | 187 (153-228) | .08 |
| High LDH, >225, n (%) | 6 (20.7) | 23 (32.4) | 29 (29) | .33 |
| UNK, n | 1 | 7 | 8 | |
| IGHV mutation status† | — | |||
| Unmutated, n (%) | 15 (78.9) | 26 (76.5) | 41 (77.4) | |
| Mutated, n (%) | 4 (21.1) | 8 (23.5) | 12 (22.6) | |
| UNK, n | 11 | 44 | 55 | |
| Richter transformation, n (%) | .4 | |||
| No | 27 (90) | 74 (94.9) | 101 (93.5) | |
| Yes | 3 (10) | 4 (5.1) | 7 (6.5) | |
| Year HCT, n (%) | <.001 | |||
| 2010-2012 | 53 (68) | 53 (49.1) | ||
| 2013-2014 | 7 (23.3) | 25 (32.1) | 32 (29.6) | |
| 2015-2018 | 23 (76.7) | 23 (21.3) | ||
| Del17p | .025 | |||
| No, n (%) | 7 (24.1) | 36 (50.7) | 43 (43) | |
| Yes, n (%) | 22 (75.9) | 35 (49.3) | 57 (57) | |
| UNK, n | 1 | 7 | 8 | |
| Complex karyotype: ≥5 abnormalities | .22 | |||
| No, n (%) | 14 (53.8) | 39 (69.6) | 53 (64.6) | |
| Yes, n (%) | 12 (46.2) | 17 (30.4) | 29 (35.4) | |
| UNK, n | 4 | 22 | 26 | |
| . | Prior therapy . | All . | P . | |
|---|---|---|---|---|
| Targeted . | CIT . | |||
| Total, N | 30 | 78 | 108 | |
| Age, median (range), y | 60 (30-71) | 59 (26-73) | 59 (26-73) | .36 |
| Sex, n (%) | .22 | |||
| Male | 25 (83.3) | 55 (70.5) | 80 (74.1) | |
| Female | 5 (16.7) | 23 (29.5) | 28 (25.9) | |
| Patient-donor sex match, n (%) | .13 | |||
| Male ← Female | 10 (33.3) | 15 (19.2) | 25 (23.1) | |
| Disease status at HCT, n (%) | .47 | |||
| CR | 6 (20) | 21 (26.9) | 27 (25) | |
| PR | 22 (73.3) | 56 (71.8) | 78 (72.2) | |
| Relapse | 1 (3.3) | 1 (1.3) | 2 (1.9) | |
| Induction failure | 1 (3.3) | 1 (0.9) | ||
| ECOG PS, n (%) | .16 | |||
| 0 | 5 (16.7) | 18 (23.1) | 23 (21.3) | |
| 1 | 18 (60) | 51 (65.4) | 69 (63.9) | |
| 2 | 7 (23.3) | 9 (11.5) | 16 (14.8) | |
| Patient and donor CMV serostatus, n (%) | .34 | |||
| R−/D− | 6 (20) | 26 (33.3) | 32 (29.6) | |
| R−/D+ | 8 (26.7) | 12 (15.4) | 20 (18.5) | |
| R+/D− | 11 (36.7) | 23 (29.5) | 34 (31.5) | |
| R+/D+ | 5 (16.7) | 17 (21.8) | 22 (20.4) | |
| HCT-comorbidity score, n (%) | .56 | |||
| 0 | 13 (43.3) | 39 (50) | 52 (48.1) | |
| 1 | 3 (10) | 13 (16.7) | 16 (14.8) | |
| 2 | 4 (13.3) | 9 (11.5) | 13 (12) | |
| ≥3 | 10 (33.3) | 17 (21.8) | 23 (25) | |
| No. of prior therapies | .41 | |||
| 1, n (%) | 2 (6.7) | 9 (11.5) | 11 (10.2) | |
| 2-3, n (%) | 12 (40) | 38 (48.7) | 50 (46.3) | |
| ≥4, n (%) | 16 (53.3) | 31 (39.7) | 47 (43.5) | |
| Median (range) | 4 (1-9) | 3 (1-10) | 3 (1-10) | .1 |
| Time from first CLL tx to alloHCT, mo* | .35 | |||
| Median (range) | 39.5 (6.7-173.3) | 39.1 (4.2-151.6) | 39.1 (4.2-151.6) | |
| Targeted therapy prior to HCT, n (%) | NA | |||
| Ibrutinib | 19 (63.3) | 20 (18.5) | ||
| Ibrutinib/idelalisib | 1 (3.3) | 2 (1.9) | ||
| Ibrutinib/venetoclax | 5 (16.7) | 4 (3.7) | ||
| Ibrutinib/CART19/ibrutinib2/venetoclax | 1 (3.3) | 1 (0.9) | ||
| Ibrutinib/idelalisib/ibrutinib2/venetoclax | 1 (3.3) | |||
| Venetoclax | 3 (10) | 3 (2.8) | ||
| HLA type (at A, B, C, DRB1), n (%) | .1 | |||
| 8/8 MRD | 10 (33.3) | 19 (24.4) | 29 (26.9) | |
| 8/8 MUD | 13 (43.3) | 50 (64.1) | 63 (58.3) | |
| 7/8 MUD | 7 (23.3) | 6 (7.7) | 13 (12) | |
| 5/8 MRD | 1 (1.3) | 1 (0.9) | ||
| 5/8 MUD | 2 (2.6) | 2 (1.9) | ||
| Cell source, n (%) | .7 | |||
| BM | 2 (2.6) | 2 (1.9) | ||
| PBSC | 30 (100) | 74 (94.9) | 104 (96.3) | |
| Double cord | 2 (2.6) | 2 (1.9) | ||
| GVHD prophylaxis, n (%) | .14 | |||
| Calcineurin inhibitor/Sir/MTX | 22 (73.3) | 43 (55.1) | 65 (60.2) | |
| Calcineurin inhibitor/MTX | 3 (10) | 21 (26.9) | 24 (22.2) | |
| Other | 5 (16.7) | 14 (18.0) | 19 (17.6) | |
| RIC regimen, n (%) | .009 | |||
| Flu/Bu1 | 7 (23.3) | 48 (61.5) | 55 (50.9) | |
| Flu/Bu2 | 21 (70) | 27 (34.6) | 48 (44.4) | |
| Other | 2 (6.7) | 3 (3.8) | 5 (4.6) | |
| WBC count, ×109/L | .001 | |||
| <2, n (%) | 2 (6.7) | 18 (23.1) | 20 (18.5) | |
| 2-10, n (%) | 21 (70) | 57 (73.1) | 78 (72.2) | |
| >10, n (%) | 7 (23.3) | 3 (3.8) | 10 (9.3) | |
| Median (IQR) | 4.6 (3.3-8.8) | 3.3 (2.1-4.7) | 3.7 (2.2-5.5) | .002 |
| % BM involvement | .22 | |||
| Median (IQR) | 5 (5-15) | 5 (5-10) | 5 (5-14) | |
| UNK, n | 1 | 9 | 10 | |
| LDH | ||||
| Median (IQR) | 164 (150-209) | 196 (155-230) | 187 (153-228) | .08 |
| High LDH, >225, n (%) | 6 (20.7) | 23 (32.4) | 29 (29) | .33 |
| UNK, n | 1 | 7 | 8 | |
| IGHV mutation status† | — | |||
| Unmutated, n (%) | 15 (78.9) | 26 (76.5) | 41 (77.4) | |
| Mutated, n (%) | 4 (21.1) | 8 (23.5) | 12 (22.6) | |
| UNK, n | 11 | 44 | 55 | |
| Richter transformation, n (%) | .4 | |||
| No | 27 (90) | 74 (94.9) | 101 (93.5) | |
| Yes | 3 (10) | 4 (5.1) | 7 (6.5) | |
| Year HCT, n (%) | <.001 | |||
| 2010-2012 | 53 (68) | 53 (49.1) | ||
| 2013-2014 | 7 (23.3) | 25 (32.1) | 32 (29.6) | |
| 2015-2018 | 23 (76.7) | 23 (21.3) | ||
| Del17p | .025 | |||
| No, n (%) | 7 (24.1) | 36 (50.7) | 43 (43) | |
| Yes, n (%) | 22 (75.9) | 35 (49.3) | 57 (57) | |
| UNK, n | 1 | 7 | 8 | |
| Complex karyotype: ≥5 abnormalities | .22 | |||
| No, n (%) | 14 (53.8) | 39 (69.6) | 53 (64.6) | |
| Yes, n (%) | 12 (46.2) | 17 (30.4) | 29 (35.4) | |
| UNK, n | 4 | 22 | 26 | |
BM, bone marrow; Bu1, busulfan 3.2 mg/kg; Bu2, busulfan 6.4 mg/kg; CMV, cytomegalovirus; CR, complete remission; D, donor; ECOG PS, Eastern Cooperative Oncology Group performance status; Flu, fludarabine; IQR, interquartile range; LDH, lactate dehydrogenase; MRD, matched related donor; MTX, methotrexate; MUD, matched unrelated donor; NA, not applicable; PBSC, peripheral blood stem cell; PR, partial remission; R, recipient; Sir, sirolimus; Targeted, prior targeted therapy; tx, treatment; UNK, unknown; WBC, white blood cell.
Four patients have missing date of the first CLL treatment in the CIT group.
Due to a high number of missing data, P value is not provided.